“We are very pleased to be invited by WFH to present our FVIII solution for home and in-office measurement of FVIII levels. Our approach provides a high-level of accuracy for FVIII measurements, particularly for long-acting and gene therapy-based FVIII therapies where conventional testing via activated partial thromboplastin time is less appropriate,” said Eugene Y. Chan, MD
The rHEALTH point-of-care FVIII solution uses this patent pending two-stage biochemistry to provide high accuracy in measurement of FVIII levels in the presence of interferents such as lupus anti-coagulant and for early detection of inhibitors. The solution is uniquely suitable for patients where such testing is unavailable.
The forum will be in the Westin Hotel in Montreal on November 13-14, 2019 and will address issues related to the safety and supply of treatment products for bleeding disorders, and bring together patient groups, regulators, representatives from industry, and not-for-profit fractionators, as well as doctors who treat people with bleeding disorders. The talk with be on November 13, 2019 at 3:00 PM EST.
